These values are estimates only
Semaglutide and tirzepatide are both glucagon-like peptide-1 GLP-1 receptor agonists, which means that they work in the same way to reduce appetite and regulate blood sugar levels
It also supports the composition and activity of the gut microbiome, promoting an increase in beneficial bacteria and the production of short-chain fatty acids
Key tips for clinicians include: Ask about gallbladder history before starting therapy Monitor for right upper quadrant pain or nausea after meals Educate patients on when to seek medical evaluation For most, the benefits of GLP1 therapy outweigh the risks, but patient awareness is critical for timely diagnosis and care
Other research demonstrates that multi-hormone weight loss therapies targeting GLP-1, GIP, and glucagon are better at preserving muscle than medications targeting only one hormone
We're in the trenches with patients, navigating the complexities of treatment plans, medication sourcing, and insurance policies